Project Grant R41AI172693
- The University of Illinois was awarded a $306,821 Project Grant from the National Science Foundation Division of Civil, Mechanical, and Manufacturing Innovation. The grant supports the Fabrication of Antimicrobial Textiles by Roll-to-Roll Electroless Plating project under the NSF Engineering program (CFDA 47.041). The project aims to develop new roll-to-roll plating processes to impart antimicrobial properties to textiles for applications such as healthcare fabrics and outdoor gear. The research...
- This National Science Foundation Project Grant of $100,000 awarded to Florida A&M University from July 1, 2022 to June 30, 2023 under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) will support the development of advanced hemp-derived fabrics with antimicrobial properties. Specifically, the grant will fund research to create an electrically conductive mesh coated with materials to generate hydroxyl radicals from air exposure. This is intended to structurally break...
- This $256,000 National Science Foundation Project Grant under the Engineering (47.041) program will support the development of a permanent ceramic antimicrobial coating technology by Nanoionix, LLC. The goal is to synthesize and deposit a pure ceramic coating on relevant substrates that exceeds EPA requirements for generating reactive oxygen species to inactivate viruses and bacteria. Nanoionix will conduct spectroscopic assessments to rapidly evaluate the types and numbers of reactive oxygen...
- This Project Grant, awarded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a unique antimicrobial vascular catheter to prevent catheter-related bloodstream infections (CRBSI). The $272,702 award, effective September 1, 2023, with a completion date of February 29, 2024, will support research and development efforts to create an intravascular catheter with inherent long-lasting antiseptic properties. The...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $299,435 to Halomine Inc. (doing business as Avantguard) to develop a novel, bio-inspired chloramine treatment for cutaneous fungal infections. The key objectives are to: Test the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the chloramine compound against a wider...
- The National Science Foundation Division of Industrial Innovation awarded Quick-Med Technologies, Inc. a $255,999 Project Grant under the Engineering federal grant program (CFDA 47.041) to develop Regenerable Antimicrobial Paints Based on Hydrogen Peroxide. This award, issued on April 1, 2021 for completion by September 30, 2021, will support Quick-Med Technologies' efforts to improve the quality of life and economic strength of the nation by fostering innovation in engineering research....
- This $196,920 National Science Foundation project grant supports research at the University of New Orleans to develop anti-microbial surfaces using additive manufacturing techniques. Specifically, the grant funds an interdisciplinary research effort to understand how embedding silver nanoparticles into polymer filaments for material extrusion 3D printing, and manipulating process parameters and part design, can influence ion release kinetics and the effectiveness of fabricated parts in...
- This $255,966 National Science Foundation Technology, Innovation, and Partnerships award to Nano-Product Engineering, LLC will support the development of an antiviral/antimicrobial micropowder for application to personal protective equipment and respiratory equipment surfaces. The award period is from September 15, 2022 through May 31, 2023. The project aims to improve the protective properties of commonly used PPE and respiratory equipment, which typically only provides passive protection and...
- This Project Grant award from the National Science Foundation's Integrative Activities (IA) program provides $275,000 to Clemson University to develop a flexible, tunable voltammetric sensor that can rapidly detect and quantify virulence signals from the Pseudomonas aeruginosa bacteria. The goal is to enable faster determination of infections caused by antibiotic-resistant bacteria, which annually lead to more than 35,000 deaths in the U.S. despite widespread antibiotic availability. The...
- Acatechol, Inc. was awarded a $274,982 National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase I grant to develop an innovative anti-infective coating for Foley catheters. The project aims to create a hybrid coating that combines biofilm-repellent and antimicrobial properties to provide prolonged resistance against pathogen colonization and catheter-associated urinary tract infections (CAUTIs). This work is being conducted under the NSF Technology, Innovation, and...
INVESTIGATION OF CHITOSAN-SUPPORTED SILVER AS A SAFE AND EFFECTIVE BROAD-SPECTRUM ANTIMICROBIAL TEXTILE FINISH - PROJECT SUMMARY MAXIMUM OF 30 LINES OF TEXT MINIMUM OF " MARGINS FONT SIZE 11 PTS OR GREATER THE OVERALL RESEARCH GOAL OF THE PROPOSED WORK IS TO TEST THE ANTIMICROBIAL ACTIVITY AND DURABILITY OF A CHITOSAN-SUPPORTED SILVER-BASED TEXTILE FINISH FOR INCORPORATION INTO HOSPITAL PRIVACY CURTAINS. FURTHERMORE, SUCCESSFUL DEVELOPMENT OF THIS TEXTILE FINISH FOR PRIVACY CURTAINS WOULD SET THE FOUNDATION FOR DEVELOPMENT OF ADDITIONAL ANTIMICROBIAL TEXTILES FOR INCORPORATION IN BED SHEETS, BLANKETS, PATIENT CLOTHING, SCRUBS, AND SURGICAL SHEETS, FOR EXAMPLE. ANTIMICROBIAL TEXTILES SERVE TO COMBAT HOSPITAL-ACQUIRED INFECTIONS WHICH AFFECT APPROXIMATELY 2 MILLION PATIENTS PER YEAR AND INCUR ANNUAL DIRECT MEDICAL COSTS OF AT LEAST $28.4 BILLION IN THE U.S. IN SUPPORT OF THE OVERALL RESEARCH GOAL, SPECIFIC AIM 1 WILL DETERMINE THE LOADING RATE OF THE CHITOSAN SILVER PRODUCT ON A VARIETY OF TEXTILES RELEVANT TO THE HEALTHCARE FIELD GIVEN A MANUFACTURING TOLERANCE OF 10%. THE CURRENT CHITOSAN SILVER PRODUCT (1% CHITOSAN AND 0.15% SILVER) WILL BE MANUFACTURED WITH A TOLERANCE OF 10% (0.9-1.1% CHITOSAN AND 0.14-0.16% SILVER) AND USED TO FINISH COTTON, POLYESTER, SPANDEX, AND TEXTILE BLENDS, WITH SUBSEQUENT DETERMINATION OF THE LOADING RATE OF THE CHITOSAN SILVER TEXTILE FINISH. RESULTS OF SPECIFIC AIM 1 WILL PROVDE THE BASIS FOR CORRELATING ANTIMICROBIAL ACTIVITY WITH CHITOSAN AND SILVER CONCENTRATIONS ON TREATED TEXTILES. SPECIFIC AIM 2 WILL DETERMINE THE ANTIMICROBIAL ACTIVITY OF THE TEXTILES PREPARED IN SPECIFIC AIM 1. FOUR ORGANISMS WILL BE USED IN TESTING: A GRAM NEGATIVE BACTERIUM, A GRAM POSITIVE BACTERIUM, A YEAST, AND A MOLD. TESTING WILL DETERMINE THE PRESENCE OF DIFFUSIBLE ANTIMICROBIAL AGENTS, INDICATIVE OF LEACHING OF THE CHITOSAN SILVER FINISH, AND FURTHER TESTING WILL DETERMINE CONTACT INHIBITION OF THE TREATED TEXTILES. RESULTS OF SPECIFIC AIM 2 WILL DETERMINE THE PRIMARY MODE OF ANTIMICROBIAL ACTIVITY, WHICH IS ANTICIPATED TO BE VIA CONTACT INHIBITION RATHER THAN LEACHING OF THE CHITOSAN SILVER FINISH. SPECIFIC AIM 3 WILL DEMONSTRATE THE DURABILITY OF THE TEXTILE FINISH DURING WASHING AND DISINFECTION. TEXTILES WILL BE WASHED, WITH AND WITHOUT BLEACH, USING TYPICAL CLEANING CONDITIONS FOR HEALTHCARE TEXTILES. ANTIMICROBIAL EFFICACY WILL BE TESTED AFTER 10, 50, AND 100 WASHES USING THE SAME METHODS AS DESCRIBED FOR SPECIFIC AIM 2. AFTER EACH WASHING STAGE, SILVER REMAINING ON THE TEXTILE WILL BE DETERMINED VIA NITRIC ACID DIGESTION AND ICP-MS. RESULTS OF SPECIFIC AIM 3 WILL DEMONSTRATE THE DURABILITY OF THE TEXTILE FINISH DURING TYPICAL CLEANING PROCEDURES, AND VERIFY THE RETENTION OF THE CHITOSAN SILVER FINISH. SPECIFIC AIM 4 IS TO DETERMINE HOW THE CHITOSAN SILVER TEXTILE FINISH ALTERS TEXTILE PROPERTIES, SPECIFICALLY, COLOR, WATER REPELLENCY, AND FLAMMABILITY. THE TREATED TEXTILES ARE ANTICIPATED TO DEMONSTRATE MINIMAL GRAYING, NO IMPACT ON WATER REPELLENCY, AND REDUCED FLAMMABILITY. TO DEMONSTRATE THE UTILITY OF THIS CHITOSAN SILVER FINISH FOR PREPARING ANTIMICROBIAL TEXTILES, THE ANTICIPATED OUTCOME IS AT LEAST A 3-LOG REDUCTION FOR ALL PATHOGENS FOR ALL TREATED TEXTILES, BOTH UNWASHED AND WASHED UP TO 50 TIMES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 7/24/24 | ||
| Not listed | $55.0k | 4/24/23 | ||
| Not listed | $254.2k | 7/12/22 | ||
| Not listed | $254.2k | 7/12/22 | ||
| Not listed | $254.2k | 7/12/22 |